Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review

Journal of Rheumatology

Volumn 26, Issue 4, 1999, Pages 966-970

  Ruof, Jörg ^a   Stucki, Gerold ^a,b  

^a Rheumaklinik und Institut fur Physikalische Medizin   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Ankylosing Spondylitis; C reactive Protein; Erythrocyte Sedimentation Rate

Indexed keywords

C REACTIVE PROTEIN;

ANKYLOSING SPONDYLITIS; ARTICLE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY;

ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CLINICAL TRIALS; DATABASES, FACTUAL; HUMANS; MEDLINE; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING;

EID: 0032914045     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S, on behalf of the Assessment in Ankylosing Spondylitis Working Group. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997:24:2225-9.
2. Boers M, Brooks P, Strand VC, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial). J Rheumatol 1998:25:198-9.
3. Resnick D, Niwayama G. Ankylosing spondylitis. In: Resnick D, editor. Diagnosis of bone and joint disorders. Philadelphia: Saunders; 1995:1008-974.
4. Bessette L, Katz N, Liang MH. Differential diagnosis and conservative treatment of rheumatic disorders. Ankylosing spondylitis. In: Frymoyer JW, editor. The adult spine. Philadelphia, New York: Lippincott-Raven; 1997:804-9.
5. Khan MA. Ankylosing spondylitis: clinical features. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1998;6.16.1-9.
6. van der Linden S. Ankylosing spondylitis. In: Kelley WN, Ruddy S, Harris ED, Sledge CB, editors. Textbook of Rheumatology. Philadelphia: Saunders; 1997:969-82.
7. Arnett FC. Ankylosing spondylitis. In: Koopman WJ, editor. Arthritis and allied conditions. Baltimore: Williams & Wilkins; 1997:1197-208.
8. Skaar O, Dale K, Lindegaard MW, Forre O, Kass E. Quantitative radio-isotope scanning of the sacroiliac joints in ankylosing spondylitis. Acta Radiol 1992;33:169-71.
9. Smith GW, Blackwell CC, Nuki G. Faecal flora in spondylarthropathy. Br J Rheumatol 1997:36:850-4.
10. Smith GW, James V, Mackenzie DAC, et al. Ankylosing spondylitis and secretor status: a re-evaluation. Br J Rheumatol 1997:36:778-80.
11. Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathwes JA. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 1986;25:171-4.
12. Nashel DJ, Petrone DL, Ulmer CC, Sliwinski AJ. C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome. J Rheumatol 1986:13:364-7.
13. Cowling P, Ebringer R, Cawdell D, Ishii M, Ebringer A. C-reactive protein, ESR, and klebsiella in ankylosing spondylitis. Ann Rheum Dis 1980:39:45-9.
14. Hickling P, Turnbull L, Dixon JS. The relationship between disease activity, immunoglobulins and lymphocyte sub-populations in ankylosing spondylitis. Rheumatol Rehabil 1982:21:145-50.
15. Dixon JS, Bird HA, Wright V. A comparison of serum biochemistry in ankylosing spondylitis, seronegative and seropositive rheumatoid arthritis. Ann Rheum Dis 1981:40:404-8.
16. Richter MB, Coughlan RJ, Panayi GS, Gordon Y. Is there more than one signal for acute phase response? J Rheumatol 1985:12:1048-52.
17. Laurent MR, Panayi GS. Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis 1983;42:524-8.
18. Treadwell BL, Tweed JM. Ketoprofen (Orudis) in ankylosing spondylitis. NZ Med J 1975:81:411-3.
19. Sturrock RD, Hart FD. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylilis. Ann Rheum Dis 1974;33:129-31.
20. Calin A, Nakache JP, Gueguen A, Zeidler H, Veys E, Dougados M. Discriminant capacity of variables in ankylosing spondylitis between placebo and fast acting drugs [abstract], Arthritis Rheum 1997:40 Suppl 9:S63.
21. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Van A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998:25:714-7.
22. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988:31:1111-6.
23. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991;10:43-8.
24. ICSH (International Council for Standardization in Haematology). Recommendation for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993:46:198-203.
25. Barclay EA, Coia JE, Kale PC, Masterton RG. Comparison of two automated quantitative immunoassays for the determination of C reactive protein concentrations. J Clin Pathol 1994;47:1119-20.
26. Gill CW, Bush WS, Burleigh WM, et al. An evaluation of a C-reactive protein assay using a rate immunonephelometric procedure. Am J Clin Pathol 1981;75:50-5.
27. Eidgenössisches Departement des Innern. Analysenliste mit Tarif [Reference price list for medical and diagnostic procedures.]. Positionsnummern 8519.00 und 8137.00. Bern 1997.
28. Franssen MJ, van de Putte LB, Gribnau FW. IgA levels and disease activity in ankylosing spondylitis: a prospective study. Ann Rheum Dis 1985:44:766-71.
29. Reynolds TL, Kahn M, van der Linden S, Cleveland RP. Differences in HLA-B27 positive and negative patients with ankylosing spondylitis: study of clinical disease activity and concentrations of serum IgA, C reactive protein, and haptoglobin. Ann Rheum Dis 1991:50:154-7.
30. Creemers MCW, Franssen MJAM, van de Putte LBA, Gribnau FWJ, van Riel PLCM. Methotrexate in severe ankylosing spondylitis. J Rheumatol 1995:22:1104-7.
31. Fraser SM, Sturrock RD. Evaluation of sulphasalazine in ankylosing spondylitis - an interventional study. Br J Rheumatol 1990;29:37-9.
32. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995:38:618-27.
33. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995:22:894-8.
34. Corkill MM, Jobanputra P, Gibson T, MacFarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 1990:29:41-5.
35. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ 1986:293:911-4.
36. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396-9 .